AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation for approval in the ...

member of the AEGEAN Steering Committee and investigator in the trial, said: "Adding perioperative durvalumab to neoadjuvant chemotherapy significantly improved outcomes for patients with ...

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

The Cambridge, England-based pharmaceuticals firm said Imfinzi, or durvalumab, in combination ... and was based on results from the Aegean phase three trial. In the trial, the drug showed a ...

The similarly designed AEGEAN trial in lung cancer ran into ... but the disease still recurs in around half of them. "Adding durvalumab before and after surgery significantly reduced the chance ...